Inflammatory liver injury is the initiating factor for various chronic liver diseases.It can involve the whole body,and on the contrary,systemic diseases may also lead to liver injury.The diagnosis and treatment of liver disease should not only consider the liver disease itself,but also understand the interaction between various systemic diseases and inflammatory liver injury and related pathophysiological mechanisms.Therefore,the diagnosis and treatment of liver injury often require multidisciplinary discussions and joint decision-making.One of the important links in the treatment of liver disease is to protect and maintain the stability of liver function,and how to carry out anti-inflammatory and liver-protecting treatment should be considered during the development of treatment strategies.Bicyclol is a chemical agent independently developed by China and is used for the treatment of inflammatory liver injury.Bicyclol has a good clinical effect in the prevention and treatment of inflammatory liver injury due to various causes and has been registered and listed in nine countries along the Belt and Road.Therefore,we have organized domestic experts from relevant disciplines all over the country to summarize the advances in the multidisciplinary clinical application of bicyclol in the prevention and treatment of inflammatory liver injury based on related guidelines/consensus statements/clinical pathways and evidence-based medicine and with reference to the clinical practice in China,in order to improve the scientific and standard use of bicyclol in clinical practice and the prevention and treatment of inflammatory liver injury in each discipline.